Abivax Stock
Abivax S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Marc de Garidel
- Employees
- 80
- Market cap
- $6.5 B
- IPO
- 20/10/2023
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm in the healthcare sector focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. The company was founded in 2013 and maintains its headquarters in Paris, France. A…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Abivax stock: price history
1D
-4.6%
1W
-0.0%
1M
-13.8%
6M
-26.7%
YTD
-34.6%
1Y
-5.1%
2Y
+770.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
21/12/2026 (in 65 days)
Volatility around earnings
~54% weaker price swings than usual
Abivax stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Abivax
Analyst assessment of Abivax
PRICE TARGET LOW
US$118.00
CONSENSUS
US$156.00
MEDIAN
US$156.50
PRICE TARGET HIGH
US$180.00
0
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 22/09/2026
Abivax stock metrics
P/E
-16.76
P/B
17.17
EV/EBITDA
-23.31
RETURN ON EQUITY
-32.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.4%
FLOAT SHARES
76,562,929
AVG. DAILY VOLUME (30D)
1,356,135
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.6%
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Abivax stock
What does Abivax do?
Abivax S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Marc de Garidel, the company employs around 80 people.
The IPO was on 20/10/2023; the stock trades on NASDAQ under the ticker ABVX.
What do analysts say about Abivax stock?
13 analysts rate the stock, the consensus is Buy (as of 22/09/2026).
The average price target is US$156.00, ranging from US$118.00 to US$180.00, with a median of US$156.50.
This is an external assessment, not a statement by Market Jury.
When does Abivax report next?
The next earnings date is 21/12/2026.
Around past earnings, price swings were roughly -54% stronger than usual.
Does Abivax pay a dividend?
No, Abivax currently does not pay a dividend.
Which stocks are comparable to Abivax?
Comparable stocks include Nanobiotix, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Abivax stock analyzed?
Clicking "Analyze stock" lets five strategies assess Abivax against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.